Curr Med Chem. 2010;17(36):4448-61.

The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia.

Hatfield KJ, Reikvam H, Bruserud Ø.

Curr Top Microbiol Immunol. 2010;341:v-vi.

The chemokine system in experimental and clinical hematology. Preface.

Bruserud Ø.

Expert Opin Ther Targets. 2010 Nov;14(11):1139-42.

Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia - the biological heterogeneity.

Bruserud Ø, Reikvam H.

Hematology. 2010 Oct;15(5):338-43.

Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia--a report of five cases.

Fredly H, Stapnes Bjørnsen C, Gjertsen BT, Bruserud Ø.

Blood. 2010 Sep 2;116(9):1389-90.

Antivascular combo therapy: up-and-coming.

Bruserud O, Hatfield K.

Eur Cytokine Netw. 2010 Sep;21(3):154-64. Epub 2010 Aug 20.

Hypoxia increases HIF-1α expression and constitutive cytokine release by primary human acute myeloid leukaemia cells.

Hatfield KJ, Bedringsaas SL, Ryningen A, Gjertsen BT, Bruserud O.

Leuk Res. 2010 Nov;34(11):1422-3. Epub 2010 Jul 16.

Heat shock protein 90 (HSP90) inhibition--from experimental to clinical studies.

Bruserud Ø, Reikvam H.

J Biomed Biotechnol. 2010;2010:692097. Epub 2010 Jun 2.

Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience.

Liseth K, Ersvaer E, Hervig T, Bruserud Ø.

BMC Immunol. 2010 Jul 9;11:38.

Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells.

Ersvaer E, Liseth K, Skavland J, Gjertsen BT, Bruserud Ø.

Genome Med. 2010 Jun 29;2(6):41.

Clinical proteomics of myeloid leukemia.

Hjelle SM, Forthun RB, Haaland I, Reikvam H, Sjøholt G, Bruserud O, Gjertsen BT.

Nutr Cancer. 2010;62(5):574-83.

Lentinan: hematopoietic, immunological, and efficacy studies in a syngeneic model of acute myeloid leukemia.

McCormack E, Skavland J, Mujic M, Bruserud Ø, Gjertsen BT.

Transfus Apher Sci. 2010 Aug;43(1):33-6. Epub 2010 Jun 16.

Minor diurnal and activity-induced variations in daytime peripheral blood platelet counts do not have any major impact on platelet yield by platelet apheresis.

Akkök CA, Hervig T, Bjørsvik S, Underdal MO, Skoug CF, Ersvaer E, Bruserud Ø.

Apoptosis. 2010 Aug;15(8):946-55.

Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005).

Hampson P, Wang K, Milverton L, Ersvaer E, Bruserud O, Lord JM.

Curr Top Microbiol Immunol. 2010;341:149-72.

The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications.

Kittang AO, Hatfield K, Sand K, Reikvam H, Bruserud Ø.

Curr Top Microbiol Immunol. 2010;341:3-12.

The chemokine system in experimental and clinical hematology.

Bruserud Ø, Kittang AO.

Eur Cytokine Netw. 2010 Mar;21(1):40-9.

Early pre-engraftment, functional, in vitro responsiveness of T lymphocytes in allotransplanted, acute leukemia patients: proliferation and release of a broad profile of cytokines, possibly predictive of graft-versus-host disease.

Liseth K, Sjo M, Paulsen K, Bruserud Ø, Ersvaer E.

Expert Opin Investig Drugs. 2010 Feb;19(2):169-83.

Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release.

Reikvam H, Hatfield KJ, Lassalle P, Kittang AO, Ersvaer E, Bruserud Ø.

Toxins (Basel). 2010 Jan;2(1):174-94. Epub 2010 Jan 22.

The Protein Kinase C Agonist PEP005 (Ingenol 3-Angelate) in the Treatment of Human Cancer: A Balance between Efficacy and Toxicity.

Ersvaer E, Kittang AO, Hampson P, Sand K, Gjertsen BT, Lord JM, Bruserud O.

Transfusion. 2010 Apr;50(4):766-75. Epub 2009 Dec 18.

Therapeutic efficacy of platelet transfusion in patients with acute leukemia: an evaluation of methods.

Apelseth TO, Bruserud O, Wentzel-Larsen T, Hervig T.

Eur J Haematol. 2010 Mar;84(3):239-51. Epub 2009 Nov 17.

Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.

Reikvam H, Hatfield KJ, Oyan AM, Kalland KH, Kittang AO, Bruserud O.

Biochim Biophys Acta. 2010 Jan;1798(1):1-8. Epub 2009 Oct 31.

Connexin-based signaling in acute myelogenous leukemia (AML).

Foss B, Tronstad KJ, Bruserud Ø.